TY - JOUR
T1 - APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
AU - Lim, Yen Ying
AU - Villemagne, Victor L.
AU - Pietrzak, Robert H.
AU - Ames, David
AU - Ellis, Kathryn A.
AU - Harrington, Karra
AU - Snyder, Peter J.
AU - Martins, Ralph N.
AU - Masters, Colin L.
AU - Rowe, Christopher C.
AU - Maruff, Paul
AU - The AIBL Research Group
PY - 2015/3/1
Y1 - 2015/3/1
N2 - The apolipoprotein E (APOE) ɛ4 allele and high levels of beta-amyloid (Aβ) are associated with episodic memory decline and risk for Alzheimer's disease. However, there is debate about independent or interactive effects of ɛ4 on Aβ-related memory decline in healthy older adults. Healthy older adults with high Aβ burden (n = 84) enrolled in Australian Imaging, Biomarkers, and Lifestyle Study were included in this study. Cognition was measured using the computerized Cogstate Brief Battery at baseline, 18-, 36-, and 54-month follow-ups. Mini Mental State Examination and Clinical Dementia Rating scales were also administered at baseline and each follow-up timepoint. Relative to Aβ+ ɛ4 noncarriers (n = 36), Aβ+ ɛ4 carriers (n = 48) showed significantly faster decline on memory tasks, which was by convention, moderate in magnitude (d = 0.40-0.47). Aβ positivity coupled with APOE ɛ4 was associated with moderately increased decline in memory over a 54-month assessment period, suggesting that, in the preclinical stages of Alzheimer's disease, the manifestation of memory decline in older adults with high Aβ is exacerbated by the presence of APOE ɛ4.
AB - The apolipoprotein E (APOE) ɛ4 allele and high levels of beta-amyloid (Aβ) are associated with episodic memory decline and risk for Alzheimer's disease. However, there is debate about independent or interactive effects of ɛ4 on Aβ-related memory decline in healthy older adults. Healthy older adults with high Aβ burden (n = 84) enrolled in Australian Imaging, Biomarkers, and Lifestyle Study were included in this study. Cognition was measured using the computerized Cogstate Brief Battery at baseline, 18-, 36-, and 54-month follow-ups. Mini Mental State Examination and Clinical Dementia Rating scales were also administered at baseline and each follow-up timepoint. Relative to Aβ+ ɛ4 noncarriers (n = 36), Aβ+ ɛ4 carriers (n = 48) showed significantly faster decline on memory tasks, which was by convention, moderate in magnitude (d = 0.40-0.47). Aβ positivity coupled with APOE ɛ4 was associated with moderately increased decline in memory over a 54-month assessment period, suggesting that, in the preclinical stages of Alzheimer's disease, the manifestation of memory decline in older adults with high Aβ is exacerbated by the presence of APOE ɛ4.
KW - Apolipoprotein E
KW - Beta-amyloid
KW - Cognitive decline
KW - Memory
KW - Preclinical Alzheimer's disease
UR - http://www.scopus.com/inward/record.url?scp=84923540976&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2014.12.008
DO - 10.1016/j.neurobiolaging.2014.12.008
M3 - Article
C2 - 25559335
AN - SCOPUS:84923540976
SN - 0197-4580
VL - 36
SP - 1239
EP - 1244
JO - Neurobiology of Aging
JF - Neurobiology of Aging
IS - 3
ER -